10.1016/j.bbamcr.2021.119087 Biochim
Entre os problemas relatados, esto reteno de lquidos, alteraes hormonais, dores articulares, aumento da presso arterial, alteraes metablicas e reaes no local da aplicao
Sigma E2011), docosapentaenoic acid (DPA, 25 M, Sigma D1797) ferrostatin-1 (fer-1, 0.011 M, Sigma, SML0583), -tocopherol (-toco, 0.11 M, Sigma, T3251), Z-VAD-FMK (0.1100 M, BD Bioscience, 550337), TNF (50 ng/ml, PeproTech), IFN (50 ng/ml, R&D), IL-1 (10 ng/ml, PeproTech), LPS (100 ng/ml, Sigma L4524), IFN (2500U/ml, PBL, 12401-1), IL-4 (10 ng/ml, PeproTech 214-14), IL-6 (20 ng/ml, PeproTech 216-16), IL-22 (10 ng/ml, PeproTech 210-22), cholic acid (1 M, Sigma C9282), deoxycholic acid (1 M, Sigma D2510), ursodeoxycholic acid (1 M, Sigma U5127),(+/)8(9)- and (+/)11(12)- and (+/)14(15)-EETs (0.25 M Cayman Chemicals, 50511, 50651, 50351), ML351 (10 M, Sigma, SML1353), PD146176 (0.5 M, Sigma, P4620), zileuton (10 M, Sigma, Z4277), NCTT-956 (2 M, Sigma, SML0499), piroxicam (20 M, Sigma, P5654), 5-HETE (200nM-1M, Cayman Chemicals, 34210), 15-HPETE (200nM-1M, Cayman Chemicals, 44720), PGE2 (50 ng/ml, Sigma, P0409), BAY117082 (10 M, Sigma, B5556), MG132 (125 nM, ApexBio, A2585)
This comprehensive guide covers starting dose recommendations based on clinical experience, proper titration schedules and escalation timing, optimal administration timing and injection technique, factors requiring dose individualization, methods for monitoring response and adjusting protocols, special dosing considerations for specific populations, combination protocols with other peptides or hormones, and troubleshooting strategies for inadequate response or excessive side effects
